{"id":"W2590842281","doi":"10.1200/jco.2014.32.4_suppl.7","title":"Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Prednisone; Abiraterone acetate; Placebo; Prostate cancer; Internal medicine; Adverse effect; Population; Ketoconazole; Urology; Randomized controlled trial; Cancer; Oncology; Gastroenterology; Androgen deprivation therapy; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003429157,0.001766076,0.003065015,0.0003324439,0.0005957158,0.001180095,0.0008234618,0.001768299,0.01356157],"category_scores_gemma":[0.003099548,0.0005949995,0.002240257,0.0003999877,0.0007410785,0.0009414428,0.0003531533,0.002813623,0.001351049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006132129,"about_ca_system_score_gemma":0.001248342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007218011,"about_ca_topic_score_gemma":0.002242485,"domain_scores_codex":[0.9988134,0.0006708443,0.0001126441,0.0001669513,0.00009755761,0.0001386491],"domain_scores_gemma":[0.9984021,0.0005194979,0.0004168147,0.00009253507,0.0001291417,0.000439984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9833168,0.003077789,0.0004345858,0.0007693372,0.001436381,0.00003043966,0.000031763,0.0001402467,0.00136825,0.00005910642,0.001371685,0.00796357],"study_design_scores_gemma":[0.972276,0.02364909,0.001950969,0.00004204363,0.001102436,0.00002424943,0.00001255629,0.0001037705,0.0001800408,0.00007814304,0.0005704668,0.00001019193],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9386964,0.01697702,0.001708105,0.002036016,0.001315306,0.01737947,0.01322423,0.0003354948,0.008327908],"genre_scores_gemma":[0.9637309,0.006158261,0.002586377,0.002412898,0.0006672372,0.01243039,0.007187607,0.00004846603,0.004777725],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01356157,"threshold_uncertainty_score":0.04536802,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1853352785079801,"score_gpt":0.4686484202466603,"score_spread":0.2833131417386802,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}